Sab bio announces second quarter 2024 financial results and provides company updates

Fda provided clearance to sab's ind appointed lucy to as chief financial officer announced founding of a new clinical advisory board miami, aug. 08, 2024 (globe newswire) -- sab bio (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today reported financial results for the second quarter ended june 30, 2024, and provided a company update. “we've had a strong quarter as we drive closer to our upcoming sab-142 milestones.
SABS Ratings Summary
SABS Quant Ranking